(Q40550975)

21 September 2017

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study (English)

1 reference

multicenter clinical trial

21 September 2017

0 references

India

0 references

visceral leishmaniasis

1 reference

1 reference

Sundar S

1

1 reference

21 September 2017

Jha TK

2

1 reference

21 September 2017

Thakur CP

3

1 reference

21 September 2017

Mishra M

4

1 reference

21 September 2017

Singh VP

5

1 reference

21 September 2017

Buffels R

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

28 August 2003

1 reference

Clinical Infectious Diseases

21 September 2017

1 reference

21 September 2017

37

1 reference

21 September 2017

6

1 reference

21 September 2017

800-804

1 reference

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

21 September 2017

1 reference

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

The increase in risk factors for leishmaniasis worldwide

21 January 2018

1 reference

Amphotericin B for second-line treatment of Indian kala-azar

21 January 2018

1 reference

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

21 January 2018

1 reference

Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex

21 January 2018

1 reference

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

21 January 2018

1 reference

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

21 January 2018

1 reference

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

21 January 2018

1 reference

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

Clinicoepidemiological study of drug resistance in Indian kala-azar

21 January 2018

1 reference

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

21 January 2018

1 reference

Drug resistance in Indian visceral leishmaniasis

21 January 2018

1 reference

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/377542

1 reference

21 September 2017

1 reference